retatrutide clinical trial results retatrutide Lilly's triple agonist achieves 16.8% weight loss in phase 3 retatrutide weight loss clinical trials

2025;83(2):e26055

Front Pharm

Researchers are particularly interested in glucagon receptor activation because it may influence: Energy utilisation Fat metabolism Overall metabolic rate Retatrutide's inclusion of glucagon receptor activity is one of the features that differentiates it from many other metabolic research peptides

You may notice that portion sizes that once seemed small now feel adequate

Participants reported a 75.8% reduction in pain on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale

serious risks are captured in a boxed warning and a set of warnings and precautions refined through post-marketing surveillance (FAERS 2024 analysis and EMA pharmacovigilance)